WealthPLAN Partners LLC Sells 13,899 Shares of Johnson & Johnson (NYSE:JNJ)

WealthPLAN Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 20.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 54,338 shares of the company’s stock after selling 13,899 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of WealthPLAN Partners LLC’s portfolio, making the stock its 23rd biggest holding. WealthPLAN Partners LLC’s holdings in Johnson & Johnson were worth $8,596,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Christopher J. Hasenberg Inc bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $31,000. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at $40,000. WFA Asset Management Corp raised its stake in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at $44,000. Finally, Disciplined Equity Management Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at $45,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Monday, June 17th. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, July 1st. Finally, Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Down 0.2 %

Johnson & Johnson stock traded down $0.35 during midday trading on Monday, hitting $149.53. 1,546,455 shares of the company’s stock were exchanged, compared to its average volume of 7,233,687. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm has a 50-day moving average of $147.94 and a two-hundred day moving average of $153.46. The company has a market cap of $359.87 billion, a PE ratio of 9.30, a P/E/G ratio of 2.52 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.68 earnings per share. As a group, analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.